Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 9068f2f5ba29689a-LAX IP: 116.62.10.13 UTC time: 2025-01-23T15:52:07+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4